Company news
Starpharma Holdings Limited news in 2016
Starpharma Holdings Limited's news releases, calls and decks from 2016, newest first.
Starpharma receives $3.5M R&D tax incentive refund
December 21, 2016
Starpharma signs license for VivaGel Condom in Iran
November 27, 2016
Additional Priostar Glyphosate Patent Allowed in US
October 27, 2016
Enrolment complete for Phase 3 VivaGel BV-R program
October 12, 2016
VivaGel condom receives regulatory approval in Canada
September 13, 2016
New DEP drug delivery program initiated with AstraZeneca
July 28, 2016
Starpharma signs license for a VivaGel condom in China
July 21, 2016
Appendix 4C - Quarterly Cashflow Reoprt
July 13, 2016
Starpharmas DEP eliminates cabazitaxel neutropenia
May 25, 2016
VivaGel active against Zika virus
May 5, 2016
DEP cabazitaxel shows complete, sustained tumour regression
April 4, 2016
Starpharma signs drug delivery license with AstraZeneca
March 30, 2016
Successful completion of VivaGel study sexually active women
March 30, 2016
Starpharma`s Bacterial Vaginosis Study gets FDA Clearance
March 30, 2016
Starpharma and Lilly Sign New Drug Delivery Collaboration
March 30, 2016
Starpharma`s partner SSL acquired by Reckitt Benckiser
March 30, 2016
Starpharma Expands Lilly Partnership
March 30, 2016
Response to an ASX Price Query
March 30, 2016
Starpharma secures FDA agreement on BV treatment Phase 3
March 30, 2016
Starpharma secures European (EMA) agreement on BV Phase 3
March 30, 2016
SPL: Terminates Reckitt agreement and signs with Ansell
March 30, 2016
SPL Commences VivaGel Bacterial Vaginosis Prevention Study
March 30, 2016
GSK awarded funds for dermal treatment with SPL`s dendrimers
March 30, 2016
Advances leading cancer therapeutic in drug delivery program
March 30, 2016
Starpharma`s VivaGel Phase 3 trials 60% enrolled
March 30, 2016
SPL`s dendrimers improve efficacy of docetaxel in animals
March 30, 2016
SPL receives FDA Special Protocol Assessment for BV Phase 3
March 30, 2016
SPL Commences pivotal phase 3 VivaGel BV treatment trials
March 30, 2016
Response to an ASX price query
March 30, 2016
Reports rapid advancement of drug delivery program
March 30, 2016
Starpharma to recoup $6 million cash for overseas R&D
March 30, 2016
Starpharma signs cancer drug agreement with AstraZeneca
March 30, 2016
Starpharma presenting at Bell Potter LifeScience Conference
March 30, 2016
SPL docetaxel superior to Taxotere across multiple cancers
March 30, 2016
Dendrimers improve anticancer efficacy lung metastasis model
March 30, 2016
VivaGel study demonstrates reduced risk of recurrent BV
March 30, 2016
Starpharma Dendrimer-Docetaxel eliminates neutropenia
March 30, 2016
SPL Signs Priostar Agrochemical Partnership with Gowan
March 30, 2016
SPLs dendrimer a potential viral conjunctivitis treatment
March 30, 2016
Reduced neurotoxicity - SPLs dendrimer enhanced oxaliplatin
March 30, 2016
ARC grant for Starpharmas targeted drug delivery
March 30, 2016
VivaGel condom receives TGA device certification
March 30, 2016
VivaGel-coated condom approved for marketing in Japan
March 30, 2016
Starpharma Interim Report and Half-year Financial Results
March 30, 2016
Starpharma completes A$18 million placement, SPP to follow
March 30, 2016
Starpharma commences Dendrimer-Docetaxel clinical trial
March 30, 2016
Starpharma clinical trial programs accelerating
March 30, 2016
FDA Grants SPA Agreement for Phase 3 Recurrent BV Trial
March 30, 2016
Starpharma receives $4.2M R&D tax incentive refund
March 30, 2016
SPP Record Date Clarification
March 30, 2016
Decks in 2016
- Shareholder Meeting (November 2016)
Shareholder meeting · 45 slides · Nov 29, 2016
- FY2016 Earnings Presentation
Earnings · 12 slides · Aug 30, 2016